Thursday, June 11

Browsing: Belantamab

Survivors

Higher Belantamab Mafodotin Dose Intensity Deepens Responses in Transplant-Ineligible NDMM

By NewsCancerMay 30, 20260

The final analysis of the phase 3 DREAMM-9 (NCT04091126) trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual…

Diagnosis

Belantamab Mafodotin Combo for R/R Multiple Myeloma Earns Approval in China

By NewsCancerApril 20, 20260

China’s National Medical Products Administration has approved belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone (BVd) as a treatment for…

Survivors

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM

By NewsCancerApril 11, 20260

Combining belantamab mafodotin-blmf (Blenrep) with lenalidomide (Revlimid) and dexamethasone (BelaRd) appeared highly active in patients with newly diagnosed multiple myeloma…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

Browsing: Belantamab

Higher Belantamab Mafodotin Dose Intensity Deepens Responses in Transplant-Ineligible NDMM

Belantamab Mafodotin Combo for R/R Multiple Myeloma Earns Approval in China

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Latest Post

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

Subscribe to Updates

What's Hot

Browsing: Belantamab